Your browser does not support iframes.
Prescription opioid analgesics are legitimately used to manage chronic pain. However, between 1997 and 2010, the per capita use of these drugs in the U.S. increased more than six-fold, as did their nonmedical use, possibly correlating with a steep increase in deaths from overdose. To address this problem, Teva is developing immediate-release technology that is capable of delaying the onset and lowering the magnitude of the clinical effects of painkillers when multiple intact tablets are ingested, thus reducing the potential for abuse and adverse consequences of overdose, whether accidental or intentional.Our approach, powered by Teva’s immediate-release technology, is unique – there are no solutions on the market anywhere today that address what the U.S. Food and Drug Administration has cited as the most critical opioid-abuse problem. In 2015, we submitted this NTE medicine to the FDA and continue to conduct clinical trials, hoping to bring it to market in 2017.